News

Andembry now available in Japan to prevent HAE attacks

Andembry (garadacimab), a first-in-class treatment to prevent swelling attacks in people with hereditary angioedema (HAE), ages 12 and older, is now available in Japan. The treatment was approved by Japan’s Ministry of Health, Labour and Welfare in February, Andembry is the first prophylactic (preventive) therapy in Japan that…

Scoring system aims to distinguish between 2 types of angioedema

A simple diagnostic score may help distinguish between two types of angioedema — mast cell-mediated angioedema and drug-induced nonallergic angioedema — in people taking angiotensin-converting enzyme (ACE) inhibitors, researchers said. They described the scoring system in the study, “Angiotensin-converting enzyme inhibitor-induced angioedema: Proposal for a diagnostic…

Minority HAE patients experience barriers to care, study suggests

People from underrepresented racial and ethnic groups who have hereditary angioedema (HAE) continue facing barriers to diagnosis and effective care, according to a recent study. These patients reported having trouble getting adequate care before their diagnosis, and though most were satisfied with the treatment they received afterward, many…

Kaken, Kalvista partner on HAE treatment sebetralstat in Japan

Kaken Pharmaceutical obtained the rights to commercialize sebetralstat, an on-demand treatment for hereditary angioedema (HAE), in Japan under a licensing agreement with the HAE treatment’s developer, Kalvista Pharmaceuticals. Under the terms of the agreement, Kalvista will be eligible to receive an upfront payment of $11 million,…

Autoimmune conditions, allergies, asthma more likely in HAE: Study

The prevalence of certain conditions — namely, allergies, autoimmune diseases, and asthma — is higher among people with hereditary angioedema (HAE) than in the general population, according to a new study from Canada. The data specifically showed that the proportion of HAE patients who reported having autoimmune conditions was…

Deucrictibant granted orphan drug status in EU for angioedemas

Deucrictibant, an oral therapy being developed for bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema, has been granted orphan drug status in the European Union. This designation, granted by the European Commission, intends to back the development of therapies to diagnose, prevent, or treat rare…

Phase 3 trial of sebetralstat for young HAE patients is fully enrolled

A Phase 3 clinical trial testing sebetralstat as an on-demand treatment for swelling attacks in children with hereditary angioedema (HAE) has completed enrollment a year ahead of schedule. The trial’s initial target enrollment was surpassed in less than seven months, according to KalVista Pharmaceuticals, which is developing…

Teens with HAE talk of disease affecting school, life quality

The symptoms of hereditary angioedema (HAE) can be very hard on adolescents, significantly affecting their health-related quality of life, particularly in regard to schooling and their social and emotional well-being, a U.S. study based on interviews with a dozen young patients reported. Those taking part, ages 12 to 17…